Navigation Links
Vion Pharmaceuticals Files Plan With Nasdaq
Date:4/15/2008

duct development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward- looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2007. In particular, there can be no assurance as to the results of any of the Vion's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

How
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amylin Pharmaceuticals to Webcast First Quarter Results
2. Paloma Pharmaceuticals to Present at the American Association for Cancer Research
3. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Pharmaceuticals & Biotechs to Share Insights for Developing Leaders in a Fast-Paced, Competitive Industry
6. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
7. Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled Bipolar Trans Carotenoid Salts and Their Uses, for Its Family of First-In-Class Molecules
8. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
9. Microbia Announces Name Change to Ironwood Pharmaceuticals
10. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
11. Memory Pharmaceuticals Receives Nasdaq Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014  ( ... that CoPatient, an online medical bill review and advocacy ... offering in the FREE WellCard Savings discount health services ... medical bill that was more than they expected to ... members reduce health care costs, WellCard Savings is pleased ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... and AALST , Belgium, AHMEDABAD, India and ... genae associates,Cardiovascular Center Aalst and J.B. Dahm, ... Core Laboratories joint venture, called imaeon., ... of medical images,analysis for clinical research projects, ...
... EDMONTON, Oct. 6 /PRNewswire-FirstCall/ - BioMS Medical ... of multiple sclerosis (MS), today,announced that the independent ... II MINDSET-01 trial of dirucotide (MBP8298) in patients,with ... recommended,that the trial continue as per the protocol., ...
... focus on a new dietary supplement resulting from years of, ... ... Del-Immune V, BOULDER, Colo., Oct. 6 On ... regulatory,cytokines Del-Immune V(R) induction and its impact on cytotoxicity of,natural killer cells" ...
Cached Biology Technology:Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm 2BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2EUPROBIO 2008 Presentation to Highlight Latest Immune Research 2
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... and security consultant, Apollo Robbins for the ... wallet.  Apollo Robbins will ... th , 2015, demonstrating some of his famous theft ...
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security ... 3.6% from 2014 to 2019. Although the U.S. market ... Canada is expected to grow at a ...
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... An accidental discovery in a laboratory at Oregon State University ... has absorbed the energies of ancient Egyptians, the Han dynasty ... a near-perfect blue pigment. Through much of recorded human ... could be used to paint things blue, often with limited ...
... are a serious threat to human society. They are also ... at the University of Gothenburg are attempting to find substances ... ensure that the drugs of today remain effective into the ... particularly serious in drugs against fungi. Fungal cells are similar ...
... This release is available in German . ... in the cells of their victim in order to ,reprogram, them. ... live, making lots of new viruses instead. Luckily, in ... ensured by the cells, own sensors that recognise alien genetic material. ...
Cached Biology News:Accidental discovery produces durable new blue pigment for multiple applications 2Slowing evolution to stop drug resistance 2Study shows link between influenza virus and fever 2
... The S. pombe Whole Genome ... location analysis of yeast (S. pombe) ... immunoprecipitation (ChIP) with Agilent DNA microarrays. ... reliable binding data with greater true ...
... is designed for easy transformation of the ... for successful transformation simply by mixing a ... cultured yeast cells. No complicated steps, such ... The kit is particularly well suited for ...
... rapid analytical to medium scale affinity purification ... vectors. Sufficient reagents are provided for purification ... under native or denaturing conditions. Crude samples ... retains STag fusion proteins. After unbound proteins ...
Request Info...
Biology Products: